English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Tumor Necrosis Factor/Sphingosine-1-Phosphate Signaling Augments Resistance Artery Myogenic Tone in Diabetes

Sauve, M., Hui, S. K., Dinh, D. D., Foltz, W. D., Momen, A., Nedospasov, S. A., et al. (2016). Tumor Necrosis Factor/Sphingosine-1-Phosphate Signaling Augments Resistance Artery Myogenic Tone in Diabetes. DIABETES, 65(7), 1916-1928. doi:10.2337/db15-1450.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Sauve, Meghan, Author
Hui, Sonya K., Author
Dinh, Danny D., Author
Foltz, Warren D., Author
Momen, Abdul, Author
Nedospasov, Sergei A., Author
Offermanns, Stefan1, Author           
Husain, Mansoor, Author
Kroetsch, Jeffrey T., Author
Lidington, Darcy, Author
Bolz, Steffen-Sebastian, Author
Affiliations:
1Pharmacology, Max Planck Institute for Heart and Lung Research, Max Planck Society, ou_2591696              

Content

show
hide
Free keywords: VASCULAR-DISEASE PATHOPHYSIOLOGY; SKELETAL-MUSCLE ARTERIOLES; FACTOR-ALPHA; ENDOTHELIAL DYSFUNCTION; HEART-FAILURE; BLOOD-FLOW; CLINICAL CONSEQUENCES; METABOLIC SYNDROME; CEREBRAL-ARTERIES; GLYCEMIC CONTROLEndocrinology & Metabolism;
 Abstract: Diabetes strongly associates with microvascular complications that ultimately promote multiorgan failure. Altered myogenic responsiveness compromises tissue perfusion, aggravates hypertension, and sets the stage for later permanent structural changes to the microcirculation. We demonstrate that skeletal muscle resistance arteries isolated from patients with diabetes have augmented myogenic tone, despite reasonable blood glucose control. To understand the mechanisms, we titrated a standard diabetes mouse model (high-fat diet plus streptozotocin [HFD/STZ]) to induce a mild increase in blood glucose levels. HFD/STZ treatment induced a progressive myogenic tone augmentation in mesenteric and olfactory cerebral arteries; neither HFD nor STZ alone had an effect on blood glucose or resistance artery myogenic tone. Using gene deletion models that eliminate tumor necrosis factor (TNF) or sphingosine kinase 1, we demonstrate that vascular smooth muscle cell TNF drives the elevation of myogenic tone via enhanced sphingosine-1-phosphate (S1P) signaling. Therapeutically antagonizing TNF (etanercept) or S1P (JTE013) signaling corrects this defect. Our investigation concludes that vascular smooth muscle cell TNF augments resistance artery myogenic vasoconstriction in a diabetes model that induces a small elevation of blood glucose. Our data demonstrate that microvascular reactivity is an early disease marker and advocate establishing therapies that strategically target the microcirculation.

Details

show
hide
Language(s): eng - English
 Dates: 2016
 Publication Status: Issued
 Pages: 13
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000378463000019
DOI: 10.2337/db15-1450
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: DIABETES
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA : AMER DIABETES ASSOC
Pages: - Volume / Issue: 65 (7) Sequence Number: - Start / End Page: 1916 - 1928 Identifier: ISSN: 0012-1797